CRM

Prezzo Salesforce

Closed
CRM
$182,96
-$2,07(-1,11%)

*Data last updated: 2026-04-08 00:43 (UTC+8)

As of 2026-04-08 00:43, Salesforce (CRM) is priced at $182,96, with a total market cap of $171,43B, a P/E ratio of 27,04, and a dividend yield of 0,90%. Today, the stock price fluctuated between $182,06 and $186,33. The current price is 0,49% above the day's low and 1,80% below the day's high, with a trading volume of 5,43M. Over the past 52 weeks, CRM has traded between $174,58 to $296,05, and the current price is -38,19% away from the 52-week high.

CRM Key Stats

Yesterday's Close$185,03
Market Cap$171,43B
Volume5,43M
P/E Ratio27,04
Dividend Yield (TTM)0,90%
Dividend Amount$0,44
Diluted EPS (TTM)7,97
Net Income (FY)$7,45B
Revenue (FY)$41,52B
Earnings Date2026-05-27
EPS Estimate3,09
Revenue Estimate$11,05B
Shares Outstanding926,51M
Beta (1Y)1.288
Ex-Dividend Date2026-04-09
Dividend Payment Date2026-04-23

About CRM

Salesforce, Inc. provides customer relationship management technology that brings companies and customers together worldwide. Its Customer 360 platform empowers its customers to work together to deliver connected experiences for their customers. The company's service offerings include Sales to store data, monitor leads and progress, forecast opportunities, gain insights through analytics and relationship intelligence, and deliver quotes, contracts, and invoices; and Service that enables companies to deliver trusted and highly personalized customer service and support at scale. Its service offerings also comprise flexible platform that enables companies of various sizes, locations, and industries to build business apps to bring them closer to their customers with drag-and-drop tools; online learning platform that allows anyone to learn in-demand Salesforce skills; and Slack, a system of engagement. In addition, the company's service offerings include Marketing offering that enables companies to plan, personalize, and optimize one-to-one customer marketing journeys; and Commerce offering, which empowers brands to unify the customer experience across mobile, web, social, and store commerce points. Further, its service offerings comprise Tableau, an end-to-end analytics solution serving various enterprise use cases; and MuleSoft, an integration offering that allows its customers to unlock data across their enterprise. The company provides its service offering for customers in financial services, healthcare and life sciences, manufacturing, and other industries. It also offers professional services; and in-person and online courses to certify its customers and partners on architecting, administering, deploying, and developing its service offerings. The company provides its services through direct sales; and consulting firms, systems integrators, and other partners. Salesforce, Inc. was incorporated in 1999 and is headquartered in San Francisco, California.
SectorTechnology
IndustrySoftware - Application
CEOMarc R. Benioff
HeadquartersSan Francisco,CA,US
Employees (FY)83,33K
Average Revenue (1Y)$498,29K
Net Income per Employee$89,48K

Salesforce (CRM) FAQ

What's the stock price of Salesforce (CRM) today?

x
Salesforce (CRM) is currently trading at $182,96, with a 24h change of -1,11%. The 52-week trading range is $174,58–$296,05.

What are the 52-week high and low prices for Salesforce (CRM)?

x

What is the price-to-earnings (P/E) ratio of Salesforce (CRM)? What does it indicate?

x

What is the market cap of Salesforce (CRM)?

x

What is the most recent quarterly earnings per share (EPS) for Salesforce (CRM)?

x

Should you buy or sell Salesforce (CRM) now?

x

What factors can affect the stock price of Salesforce (CRM)?

x

How to buy Salesforce (CRM) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Salesforce (CRM) Latest News

2026-04-02 07:19

OpenAI高管发声:AI浪潮下传统软件不死,反而迎来价值重估

Gate News 消息,OpenAI首席运营官Brad Lightcap近日表示,在人工智能快速发展的背景下,传统软件企业并未被边缘化,反而正在积极转型,将AI能力深度整合进现有产品体系。他在播客节目中指出,多数软件公司正以接近初创企业的速度推进创新,同时依托长期积累的客户关系,具备独特竞争优势。 这一表态出现在软件股经历大幅回调之后。自2026年2月以来,市场对AI替代传统软件的担忧加剧,包括Salesforce、微软、Oracle及Snowflake在内的科技公司股价普遍下跌约24%至30%。部分投资者担心,企业未来可能借助人工智能自建工具,从而削弱传统SaaS商业模式。 不过,行业内部观点并不一致。Asana首席执行官Dan Rogers认为,AI代理的普及将显著增加协作复杂度,反而强化对工作管理软件的需求。他指出,人类与大量AI系统之间的协同,将推动企业软件向更高层次演进。与此同时,a16z合伙人Anish Acharya也表示,使用AI替代ERP或CRM系统的成本优势有限,难以形成颠覆性替代。 英伟达首席执行官黄仁勋同样否认“软件被取代”的观点,强调人工智能的发展依赖现有软件基础设施,而非完全重建体系。 在此背景下,市场开始重新审视AI与传统软件的关系。分析人士认为,随着企业加速AI部署,具备数据、客户资源和产品整合能力的软件公司,或将在下一轮技术周期中实现价值修复。

2026-03-16 06:01

27 家 SaaS 公司在 SEC 文件中将 AI agent 列为竞争风险,高管公开表态却淡化威胁

Gate News 消息,3 月 16 日,今年以来已有 27 家软件公司在证券备案文件中将 AI agent 列为竞争风险因素,去年同期仅有 7 家。但这些公司的高管在财报电话会上普遍淡化这一威胁,备案措辞与公开表态形成鲜明反差。 设计工具 Figma 上月提交的 10-K 文件写道,agentic AI「可能改变人们访问和使用数字产品的方式,从而减少对传统软件应用的依赖」。同日的财报会上,CEO Dylan Field 却表示「人类会继续使用软件,agent 也会」,并称「如果你现在愿意把关键任务交给 agent 无人监管地执行,你是个非常勇敢的人」。Figma 目前股价低于去年的 IPO 发行价。 客户关系管理平台 HubSpot 2 月年报直接提到,客户可以用 AI 自建 CRM 工具,甚至点名「vibe coding」(自然语言编程)为潜在替代路径。该公司股价过去六个月已跌去近一半。企业人力资源平台 Workday 3 月初的 10-K 文件则承认公司在「维持市场差异化」方面可能面临挑战,并警告其新推出的 Flex Credits(按 agent 用量收费的计费模式)「可能遭遇客户阻力」。前 CEO Carl Eschenbach 今年 1 月还在说「AI 对我们是顺风,绝对不是逆风」,上月已卸任。 Adobe 1 月年报也写明面临「提供生成式和 agentic AI 解决方案的公司带来的日益激烈的竞争」,但即将卸任的 CEO Shantanu Narayen 上周仍称公司产品「独特设计」以满足 AI agent 时代的企业需求。Adobe 今年股价已跌 28%。 这波恐慌被投资者称为「SaaS 末日」(SaaSpocalypse)。2 月 Anthropic 发布 Claude 新 agent 工具后,软件板块数日内蒸发约 8500 亿美元市值。SEC 2005 年起强制要求上市公司在备案文件中披露重大风险因素,这一机制客观上允许管理层在公开场合做出更乐观的预测,备案文件则承担了风险告知义务。

2026-03-10 16:21

Salesforce 计划发行最高 250 亿美元债券用于股票回购

Gate News 消息,3 月 10 日,据知情人士透露,客户关系管理(CRM)软件公司 Salesforce 正计划发行最高 250 亿美元的债券以资助股票回购,这将成为该公司历史上规模最大的债券发行。知情人士表示,该公司计划在美国市场发行至少 200 亿美元的债券。由于相关细节尚未公开,消息人士要求匿名。知情人士还称,这批债券最早可能在本周发行,但具体时间仍可能发生变化。

2026-02-26 15:17

TradFi上涨提醒:CRM上涨超8%

Gate News bot 消息,据 Gate TradFi 最新数据,CRM短时上涨 8% ,当前波动幅度明显高于近期平均水平,市场活跃度上升。

2026-02-10 05:36

a16z合伙人直言“Vibe Code神话破灭”:并非所有软件都适合AI编程

风投机构Andressen Horowitz(a16z)普通合伙人Anish Acharya在最新一期“20VC”播客中表示,认为所有软件都可以用“Vibe Code”(人工智能辅助编码)构建的观点“完全错误”。他指出,企业不应将AI编程工具无差别应用到每一个业务模块,否则不仅节省有限,还可能放大系统风险。 Acharya解释称,软件成本通常仅占企业总成本的8%至12%。即使全面使用AI辅助编码,最多也只能节约约10%的软件支出,对整体成本结构影响十分有限。如果将这类工具用于ERP、薪资系统或CRM等关键业务模块,反而可能因安全、稳定性和合规问题带来更高隐性成本。 他直言,当前的生成式模型具备强大的创新能力,更适合用在推动核心业务、创造新产品或提升运营效率上,而不是“重建已经高度成熟的企业软件体系”。他还点名Salesforce、微软、Oracle和SAP等厂商的产品,认为这些系统不应被简单替代。 Acharya同时警告,市场正在过度放大“AI会重写一切软件”的叙事,这种预期与现实存在明显偏差。“肯定会有一些企业被淘汰,但说整个软件行业都会被AI取代,是一种被炒作出来的幻觉。” 值得注意的是,他的表态发生在科技股经历一轮大幅调整之后。此前,Anthropic推出面向法律行业的AI工具,引发投资者对传统软件模式受冲击的担忧,拖累了相关板块表现。 在看待AI长期价值上,Acharya与知名投资人Vinod Khosla观点相近,认为不应只盯着股价波动。Khosla曾表示,只要API调用量保持高位,说明真实需求依旧存在,所谓“AI泡沫”并不成立。 这场关于Vibe Code和AI编程边界的讨论,也被视为2026年企业技术路线选择的重要风向标。

Hot Posts su Salesforce (CRM)

MaticHoleFiller

MaticHoleFiller

2 ore fa
证券代码:300363 证券简称:博腾股份 公告编号:2026-022号 一、重要提示 本年度报告摘要来自年度报告全文,为全面了解本公司的经营成果、财务状况及未来发展规划,投资者应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 天健会计师事务所(特殊普通合伙)对本年度公司财务报告的审计意见为:标准的无保留意见。 非标准审计意见提示 □适用 √不适用 公司上市时未盈利且目前未实现盈利 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 公司经本次董事会审议通过的利润分配预案为:以扣除公司回购专户上已回购股份后的总股本 542,182,176为基数,向全体股东每10股派发现金红利0.90元(含税),送红股0股(含税),以资本公积金向全体股东每10股转增0股。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 注:2025年11月6日,重庆正式设立两江新区行政区,公司办公地所在街道整合至新的两江新区行政区。 2、报告期主要业务或产品简介 公司是一家在全球范围内为制药企业、生物科技公司、科研机构等提供全类别、端到端服务的医药研发生产外包组织(CDMO),能够为小分子药物、大分子药物、细胞与基因治疗及新分子等不同类型的药物及疗法提供CDMO服务,具体包括:(1)小分子原料药业务,为公司核心基石业务,主要为客户提供化学药开发及上市过程所需的起始物料、中间体及原料药的工艺路线设计、工艺开发、工艺优化、分析方法开发、中试级生产、CMC注册支持、质量研究和分析研发、商业化生产等一系列定制研发及生产服务;(2)小分子制剂业务,主要为客户提供小分子药物开发所需制剂处方工艺开发及优化、分析方法开发及验证、复杂制剂开发、改良剂型开发等定制研发与生产以及共同开发服务;(3)细胞与基因治疗业务,主要以控股子公司苏州博腾为运营主体,搭建了质粒、细胞治疗、基因治疗、溶瘤病毒、核酸治疗及活菌疗法等CDMO平台,为客户提供从建库、工艺方法及分析方法开发、cGMP生产到制剂灌装的端到端服务;(4)新分子业务,主要为多肽与寡核苷酸、蛋白与偶联药物等药物提供定制研发及生产服务。 报告期内,公司核心基石业务小分子原料药业务收入占比约90%,同比增长约13%;新兴业务(小分子制剂业务、细胞与基因治疗业务、新分子业务)收入占比约9%,同比增长约26%。 截至报告期末,公司累计服务客户已达1,400余家,拥有超过5,000个项目的成功交付记录,服务终端药物包括抗病毒、抗肿瘤及免疫机能调节、抗感染、神经系统、心血管、消化道及代谢、罕见病等重大疾病治疗领域。 3、主要会计数据和财务指标 (1) 近三年主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 元 ■ (2) 分季度主要会计数据 单位:元 ■ 上述财务指标或其加总数是否与公司已披露季度报告、半年度报告相关财务指标存在重大差异 □是 √否 4、股本及股东情况 (1) 普通股股东和表决权恢复的优先股股东数量及前10名股东持股情况表 单位:股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 公司是否具有表决权差异安排 □适用 √不适用 (2) 公司优先股股东总数及前10名优先股股东持股情况表 □适用 √不适用 (3) 以方框图形式披露公司与实际控制人之间的产权及控制关系 ■ 5、在年度报告批准报出日存续的债券情况 □适用 √不适用 三、重要事项 1.2025年总体经营情况 2025年,受Biotech短期融资环境和创新药供应链区域化的影响,中国CDMO行业总体依然面临市场需求和竞争的挑战。但是,行业仍不乏在高价值管线、新兴分子领域的重要商业机会和增长驱动。2025年,是公司扭亏为盈、重回增长的突破之年。公司自第二季度实现扭亏为盈后,在下半年维持盈利,成功达成“收入恢复增长,利润扭亏为盈”的年度重要经营目标。2025年,公司在收入利润增长的同时,经营性现金流持续稳健向好,实现经营性现金流量净额7.57亿元,同比大幅增长87%。 2025年,公司实现营业收入34.20亿元,同比增长约14%。从业务板块看,报告期内公司营业收入增长来自小分子原料药业务,以及细胞与基因治疗和新分子业务等两大新业务板块,其中小分子原料药业务收入同比增长约13%、细胞与基因治疗业务同比增长约36%、新分子业务同比增长约224%;公司小分子制剂业务板块收入同比下降约4%,主要是国内仿制药制剂业务需求受集采政策带来的市场需求下滑影响。从市场单元来看,2025年,公司美国市场增长21%,中国市场同比增长39%,欧洲市场同比下降12%,日韩等其他海外市场同比增长20%。2025年,按业务板块和市场单元划分的营业收入分布如下: ■ 2025年,公司实现归属于上市公司股东的净利润9,633.99万元,实现扭亏为盈,盈利改善的主要原因是:1、公司营业收入同比增长近14%,规模化效应显现,带动公司整体毛利率提升;2、公司压实降本增效举措,费用继续保持稳中有降,四大费用合计同比下降约3%。 报告期内,公司整体毛利率近30%,同比提升约5个百分点。按市场区域分,海外市场毛利率约41%;国内市场毛利率约6%。剔除新业务亏损影响后,公司整体毛利率约39%,同比提升约7个百分点;国内市场毛利率约21%,同比提升5个百分点。 如下表所示,2025年,新业务对归属于上市公司股东的净利润影响合计约为-2.08亿元,减亏约734万元。其中,小分子制剂业务亏损8,500万元,同比减亏644万元;细胞与基因治疗业务亏损(指对上市公司合并报表影响金额)4,931万元,同比减亏918万元;新分子业务亏损7,355万元,同比增加亏损828万元,主要系新分子业务上海奉贤及外高桥基地新增折旧约1,467万元所致。 ■ 注:报告期内,基于小分子制剂及新分子业务存在跨体系交叉运营的实际情况,为更好地反映公司相关业务的实际经营状况,调整相关业务数据口径,并同时更新2024年同期数据。 2025年,公司各场地共计接受并通过181次质量审计,其中包括16次监管机构质量审计,165次客户及第三方质量审计。报告期内,公司上海外高桥、上海奉贤及重庆两江新区制剂工厂均顺利通过欧盟QP审计,为新分子业务及制剂业务海外市场开发奠定良好基础。 2.各业务板块经营情况 (1)小分子原料药业务 2025年,公司围绕年初重点工作计划,巩固CRM(市场到线索、线索到订单、管理客户关系)变革成果,通过深入、全面的市场洞察和客户开发计划,提升高价值客户、高价值管线的市场份额以及海外biotech市场的覆盖率。除当前制药行业客户外,公司以现有工艺研发技术和集成供应链能力为依托,积极开发健康消费品市场,并成功进入一家海外大客户供应链。报告期内,公司在美国和亚太市场扩大营销团队,为未来市场覆盖和份额提升奠定基础。2025年,公司为全球390余家客户提供小分子原料药服务,引入新客户98家(美国区51家,中国区28家,欧洲区10家,日韩等其他亚太区9家)。 从项目管线来看,2025年,公司小分子原料药业务收到客户询盘总数1,500余个,同比有所下降,主要是公司自2024年底开始执行早期项目订单门控机制,推动业务前端从“提量”到“提质”。报告期内,公司已签订单项目数(不含J-STAR)671个,其中新项目193个;实现交付项目数645个,其中临床前及临床一期276个,临床二期104个,临床三期58个,新药上市申请阶段23个,已上市阶段184个(详见图1)。 2025年,公司服务客户管线中共9个创新药获国内外监管批准上市,其中5个获FDA批准,4个获NMPA批准。 图1:小分子原料药业务交付项目数(单位:个) ■ 2025年,公司服务API产品数203个,同比基本持平;API产品实现收入5.45亿元,占公司总收入的16%,同比增长约6%(详见图2)。公司完成工艺验证项目(Process Validation,简称PV项目)6个,执行中的PV项目20个。工艺验证作为药物上市前的重要工作,通过PV项目积累,将有效提升公司服务项目粘性、扩大公司潜在商业化项目储备池。 / 图2:API产品收入及项目数 ■ (2)小分子制剂业务 2025年,尽管创新药制剂CDMO业务在订单和收入端均保持增长,但受国内集采政策的影响,仿制药制剂CDMO业务市场需求大幅下滑,公司小分子制剂业务整体面临挑战,收入同比下降约4%。虽然报告期内收入略有下滑,但公司通过内部提升精益运营,小分子制剂业务达成减亏经营目标。 2025年,公司小分子制剂业务服务订单客户数136家,服务订单项目数159个,引入新客户30家,新签订单约1.34亿元。报告期内,公司持续强化中美两地协同服务,“原料药+制剂”一体化协同服务客户48家,公司美国子公司J-STAR制剂服务收入同比增长约112%。 (3)细胞与基因治疗业务 2025年,通过持续加强内部运营管理,落实降本增效举措,细胞与基因治疗业务实现连续两年减亏。报告期内,细胞与基因治疗业务服务订单客户107家,服务订单项目186个,引入新客户81家,新项目119个,新签订单1.89亿元。报告期内,子公司博腾生物在市场端取得多个突破:新增5个临床期及商业化工艺变更阶段的CMC项目;成功签署多个慢病毒/mRNA-tLNP的in vivo CAR-T管线项目;成功签署多个包括CIK、TCR-T、CAR-NK/NK、UCAR-T、iPSC、MSC等新兴疗法项目;获得首个韩国客户订单;在欧洲市场成功签署首个海外慢病毒in vivo CAR-T订单。在交付端,博腾生物助力客户取得7个中美临床批件,覆盖CAR-T、UCAR-T、双靶点CAR-T、NK、CAR-NK及溶瘤病毒疗法,保持“零发补”的出色纪录;完成首个in vivo CAR慢病毒项目工艺开发及三批GMP批次生产。 (4)新分子业务 2025年,公司新分子业务新签订单7,875万元,服务订单客户59家,服务订单项目98个,涵盖临床早期(IND)、临床三期和NDA等不同阶段,并实现67个项目的阶段性交付,涵盖RDC、AOC、APC等复杂项目类型。2025年,ADC业务实现海外订单和交付的破局,获得海外双载荷(Dual-Payload)ADC IND整包项目订单;多肽和有效载荷-连接子(Payload-linker)业务均实现NDA项目破局。随着奉贤工厂中试产能投用,2025年,奉贤工厂共计交付20个新分子项目,逐步建立良好的交付记录。2025年6月,公司上海奉贤工厂及外高桥研发生产基地先后通过欧盟质量受权人(QP)审计,为新分子业务拓展全球市场奠定基础。 3.能力建设情况 2025年,公司围绕营销、研发、生产等业务核心领域,持续推进数字化与AI能力建设。报告期内,公司通过深入推进数智化与人工智能技术在医药研发制造全产业链的深度融合,荣获工信部首批“卓越级智能工厂”及重庆市“AI赋能示范型工厂”等多项荣誉。公司初步构建了覆盖营销、研发、生产及办公全场景的数智化赋能体系,推动人工智能技术从辅助工具向核心生产要素转变,实现核心业务效率与经营效益的提升。2025年,公司通过数字化赋能业务提效,识别出跨工厂物料与设备资源共享、长寿工厂AI送检计划、研发设备使用率分析等32项提效专项场景,对增加业务收入、降低成本、提升效率、提高质量等各个维度均有不同程度的改善和优化。2025年,公司完成五年 AI 发展战略规划的编制,为长期智能化发展奠定坚实基础。 2025年,公司坚定践行可持续发展理念,与各利益相关方保持积极沟通,持续推动ESG管理绩效提升,助力公司长远稳健发展。报告期内,公司近期碳减排目标顺利通过SBTi验证,同时公司还制定了覆盖能源消耗、水资源、废弃物管理在内的2030环境目标,以目标引领绿色发展,并通过运营改善、绿电采购等方式,稳步推进目标落地。此外,公司制定《供应商行为准则》,进一步将ESG相关要求融入供应链管理全流程,携手合作伙伴共建可持续供应链。2025年,在全球知名企业社会责任评级服务提供商EcoVadis评估中,公司重庆长寿工厂首次获得“金牌”认证,跻身全球参评企业前5%行列;公司还成功入选中国上市公司协会2025年上市公司可持续发展优秀实践案例、重庆市民营企业社会责任优秀案例(2025)。 海量资讯、精准解读,尽在新浪财经APP
0
0
0
0
PositionPhobia

PositionPhobia

3 ore fa
Just caught something interesting in the software market right now. There's been this massive selloff in legacy software and SaaS stocks - we're talking bear market territory with over 30% declines from September peaks. All because people are freaking out that AI is going to replace traditional software providers. But here's the thing that caught my attention: some serious analysts think this fear is way overblown. Nvidia's Jensen Huang literally said at an event that the idea software is being replaced by AI is "the most illogical thing in the world." And honestly, he's got a point. Most enterprises have spent decades building infrastructure around these platforms - they're not going to rip it all out for unproven tech. Wedbush analyst Dan Ives sees this as a legitimate buying opportunity. He's identified five stocks he thinks are deeply undervalued right now, and I've been looking at his thesis. Microsoft is down 25% from its peak and trading at 25x earnings. Ives sees 42% upside from here. Makes sense when you think about it - they're basically embedded in every enterprise, they've invested heavily in AI through OpenAI, and they've integrated AI capabilities across their entire product suite. Azure Cloud adoption is strong, with demand exceeding supply according to their CFO. CrowdStrike is one I found particularly compelling for anyone watching AI security stocks. Down 25% from peak, trading at 22x sales, with a 44% upside target. This is a cloud-native cybersecurity leader that's actually built AI into its DNA. Their Falcon platform secures against AI-powered attacks - which is becoming increasingly critical. The irony is their stock got swept up in the broader software selloff even though they're on the right side of the AI trend. Snowflake has dropped 35% and is trading at just 13x sales. Ives targets $270, implying 51% upside. Their data management platform actually benefits from AI adoption, not threatened by it. They provide the secure environment where AI workflows can safely access enterprise data. Salesforce pioneered CRM decades ago and has been early to AI adoption. They've got this massive moat of historical data and already launched their Agentforce AI agent suite. Down 44% from peak, Ives sees 103% upside potential. Then there's Palantir - the controversial one. Trading at 210x earnings (yeah, that's wild), down 36% from peak. But Ives thinks this is a game-changer for enterprise AI solutions, particularly in mission-critical use cases where they have virtually no competition. His longer-term thesis suggests 209% upside if the company trajectory continues. The broader point here is that the market might be confusing "AI will disrupt software" with "all software stocks will crash." Reality check: enterprises need both AI and the infrastructure to run it safely. That's where these companies come in. Worth keeping an eye on if you're looking at the intersection of enterprise adoption and AI security stocks right now.
0
0
0
0
SleepTrader

SleepTrader

4 ore fa
* * * **Discover top fintech news and events!** **Subscribe to FinTech Weekly's newsletter** **Read by executives at JP Morgan, Coinbase, Blackrock, Klarna and more** * * * **B2BROKER Introduces Turnkey Solution for Prime-of-Prime Liquidity Providers** ------------------------------------------------------------------------------- ### The offering targets financial firms looking to enter the institutional liquidity space without building infrastructure from scratch. B2BROKER has announced the launch of Liquidity Provider Turnkey, a new product designed to help financial institutions set up and operate their own Prime-of-Prime (PoP) liquidity businesses. The solution is aimed at brokers, trading firms, hedge funds, and **fintech companies** seeking a ready-to-deploy institutional liquidity infrastructure. The launch comes at a time when demand for institutional trading services in both traditional and digital asset markets is growing, while regulatory and technological requirements continue to increase. According to the company, the solution addresses a gap in the market for businesses that want to operate as liquidity providers but lack the resources or expertise to build the necessary systems internally. **Features and Capabilities** ----------------------------- Liquidity Provider Turnkey includes access to over 1,500 trading instruments across multiple asset classes, including forex, cryptocurrencies, equities, and commodities. The system offers a unified margin account, net open position (NOP) tracking, and deep integration with various technology partners. The product is structured to reduce the complexity and cost of launching a PoP liquidity business. Built-in features include real-time balance monitoring, dynamic margining, and integrated know-your-customer (KYC) tools. In addition, users receive support for compliance across Tier-1 and Tier-2 regulatory jurisdictions. B2BROKER also includes continuous technical support and consulting services as part of the package, positioning the product as a full-service solution for institutions entering the space. **Additional Infrastructure and Integration** --------------------------------------------- Beyond trading capabilities, the turnkey solution comes with a set of operational tools such as a customizable website, centralized CRM system, and search engine optimization components. Payment integrations are also included through B2BINPAY and EQWIRE, which provide multi-currency account functionality and automated transaction flows, including crypto processing. These components are intended to streamline onboarding, client management, and financial transactions, all within a unified platform. **Revenue and Monetization Model** ---------------------------------- Clients using the product can generate revenue through standard liquidity provider channels, including spreads, commissions, swaps, and treasury operations. The solution follows a risk-free liquidity provision model, allowing firms to act as intermediaries rather than principal counterparties. The business model also enables further monetization through integration with other B2BROKER services. The company’s broader product suite, which includes B2CORE (client management), B2TRADER (matching engine), and B2COPY (copy trading platform), is available for cross-selling or expansion. **Market Context** ------------------ Turnkey solutions have become more common in recent years, particularly in the retail brokerage space. However, ready-made infrastructure for liquidity providers has been limited. B2BROKER’s product enters the market with a focus on speed, regulatory alignment, and operational simplicity. According to the company, this release reflects growing interest from financial firms in expanding into institutional-grade services without taking on the cost and risk associated with custom infrastructure development.
1
0
0
0